Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
Article in Expert Review of Pharmacoeconomics & Outcomes Research (July 2024)